These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39059614)

  • 1. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer.
    Tan Y; Zhu Q; Yang M; Yang F; Zeng Q; Jiang Z; Li D
    Pharmacol Res; 2024 Sep; 207():107314. PubMed ID: 39059614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
    Zhou L; Xu Q; Huang L; Jin J; Zuo X; Zhang Q; Ye L; Zhu S; Zhan P; Ren J; Lv T; Song Y
    Cancer Lett; 2021 Mar; 500():163-171. PubMed ID: 33278498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
    Wang H; Xia L; Yao CC; Dong H; Yang Y; Li C; Ji WX; Sun RM; Duan HQ; Mengzhou W; Xia WM; Wang SJ; Ji P; Li Z; Jiao L; Wang Y; Lu S
    Cancer Sci; 2022 Mar; 113(3):838-851. PubMed ID: 34927309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer.
    Chen Z; Ji W; Feng W; Cui J; Wang Y; Li F; Chen J; Guo Z; Xia L; Zhu X; Niu X; Zhang Y; Li Z; Wong AST; Lu S; Xia W
    Sci Transl Med; 2024 Sep; 16(763):eadl3598. PubMed ID: 39231239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING.
    Bharti V; Kumar A; Wang Y; Roychowdhury N; de Lima Bellan D; Kassaye BB; Watkins R; Capece M; Chung CG; Hilinski G; Vilgelm AE
    JCI Insight; 2024 Jun; 9(15):. PubMed ID: 38900577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.
    Gui H; Nie Y; Yuan H; Jing Q; Li L; Zhu L; Chen S; Wang M; Wan Q; Lv H; Nie Y; Zhang X
    Oncol Rep; 2024 Nov; 52(5):. PubMed ID: 39301655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8
    Chen C; Zhao F; Peng J; Zhao D; Xu L; Li H; Ma S; Peng X; Sheng X; Sun Y; Wang T; Dong H; Ding Y; Wu Z; Liang X; Gao L; Wang H; Ma C; Li C
    Cell Rep Med; 2024 Aug; 5(8):101686. PubMed ID: 39168104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD161
    Qu J; Li Y; Wu B; Shen Q; Chen L; Sun W; Wang B; Ying L; Wu L; Zhou H; Zhou J; Zhou J
    Oncoimmunology; 2024; 13(1):2371575. PubMed ID: 38952673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
    Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined model of serum neutrophil extracellular traps, CD8
    Guo J; Shu T; Zhang H; Huang N; Ren J; Lin L; Wu J; Wang Y; Huang Z; Bin J; Liao Y; Shi M; Liao W; Huang N
    FEBS J; 2024 Aug; 291(15):3403-3416. PubMed ID: 38661680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.